Celldex Therapeutics Inc (CLDX) 17.06 $CLDX
3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 1.68 (unch), CLVS: 59.05 (+3.35), CLDX: 17.06 (+1.64), AZN: 71.43 (+0.67), GSK: 45.10 (-0.27)
Strong On High Volume: Celldex Therapeutics (CLDX)
at The Street - Wed Oct 15, 9:01AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
CLDX: 17.06 (+1.64)
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics
PR Newswire - Wed Oct 15, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation (NASDAQ: GERN), and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 14, 2014, the NASDAQ Composite ended at 4,227.17, up 0.32%, the Dow Jones Industrial Average edged 0.04% lower, to finish the day at 16,315.19, and the S&P 500 closed at 1,877.70, up 0.16%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, with the index also declining 1.35% in the previous three months. Register for your complimentary reports on these five stocks at:
GERN: 2.34 (+0.13), NVAX: 5.48 (-0.32), CLDX: 17.06 (+1.64), GALE: 2.06 (+0.06), ARIA: 5.97 (+0.23)
Celldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology
GlobeNewswire - Tue Sep 30, 3:08PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today the publication of two papers highlighting early studies of glembatumumab vedotin in breast cancer and metastatic melanoma in the Journal of Clinical Oncology (JCO). The papers, "A Phase 1/2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma" and "A Phase 1/2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Locally Advanced or Metastatic Breast Cancer" have been published as Early Release Articles on JCO's website and will appear in a future print edition.
CLDX: 17.06 (+1.64)
Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) announced the commencement of a pilot study on CDX-301 alone and in combination with Mozobil for hematopoietic stem cell transplantation.
CBM: 19.88 (+1.34), GILD: 113.45 (+0.86), CLDX: 17.06 (+1.64), AMGN: 157.19 (+8.99)
Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
GlobeNewswire - Thu Sep 25, 7:05AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation (HSCT). The study will explore the utility of CDX-301, also known as FMS-like tyrosine kinase-3 ligand or Flt3L, alone and in combination with Mozobil(R) and is supported by preclinical data demonstrating that the combination of CDX-301 and Mozobil increased hematopoietic stem cell mobilization and improved transplantation of mobilized cells.
CLDX: 17.06 (+1.64)
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
SHPG: 197.80 (+1.93), MRK: 55.85 (-0.60), CLDX: 17.06 (+1.64), GSK: 45.10 (-0.27), BMY: 54.20 (+0.67), REGN: 397.89 (-9.27), NVS: 92.35 (+2.14)
Global Burkitt Lymphoma Therapeutics Pipeline Review 2014 - 10 Drug Profiles from 4 Companies
M2 - Tue Sep 16, 11:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pgt84p/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Seattle Genetics, Inc. - Celldex Therapeutics, Inc. - Constellation Pharmaceuticals, Inc. Drug Profiles - varlilumab - SGN-CD19A - NSC-678515 - AZD-6738 - SH-7139 - Small Molecules to Inhibit BET for Cancer - Monoclonal Antibody Conjugated to Target CD20 for CLL and Burkitt Lymphoma - M-921 - SH-7133 - SH-7129 For more information visit http://www.researchandmarkets.com/research/pg...t_lymphoma
SGEN: 36.37 (+0.98), CLDX: 17.06 (+1.64), AZN: 71.43 (+0.67)
Why You Shouldn't Bet Against Celldex Therapeutics (CLDX) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:00AM CDT
Celldex Therapeutics (CLDX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 67 out of more than 250 industries.
CLDX: 17.06 (+1.64)
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
NWBO: 4.93 (+0.11), MRK: 55.85 (-0.60), DNDN: 1.06 (+0.05), CLDX: 17.06 (+1.64), NLNK: 34.90 (-3.02), GALE: 2.06 (+0.06), IMUC: 0.70 (+0.01), NVS: 92.35 (+2.14)
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
SYN: 1.61 (+0.01), CPRX: 2.72 (+0.08), GERN: 2.34 (+0.13), CLDX: 17.06 (+1.64), NPSP: 28.12 (+0.80)
Celldex Announces Upcoming Presentation at the Morgan Stanley Healthcare Conference
GlobeNewswire - Wed Sep 03, 1:00PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Morgan Stanley Healthcare Conference on September 8, 2014 at 1:25 p.m. ET at the Grand Hyatt in New York City.
CLDX: 17.06 (+1.64), MS: 34.36 (+0.40)
Critical Alerts For General Electric, DSW, Celldex Therapeutics, Cognizant Technology Solutions and 3M Released By InvestorsObserver
PR Newswire - Wed Aug 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GE, DSW, CLDX, CTSH and MMM.
DSW: 31.26 (+0.66), MMM: 151.06 (+1.50), GE: 25.88 (+0.36), CLDX: 17.06 (+1.64), CTSH: 46.93 (+1.41)
Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:51AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose a little over 9% on the day.
CBPO: 57.78 (+1.66), CBM: 19.88 (+1.34), GILD: 113.45 (+0.86), CLDX: 17.06 (+1.64)
Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 9.10% Rise
Comtex SmarTrend(R) - Tue Aug 26, 4:36PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $15.07 to a high of $17.00. Yesterday, the shares gained 9.1%, which took the trading range above the 3-day high of $15.33 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 17.06 (+1.64)
Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
at The Street - Fri Aug 22, 12:19PM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
CLDX: 17.06 (+1.64)
Celldex Therapeutics Falls 5.29% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 21, 5:14PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $14.08 to a high of $15.23. Yesterday, the shares fell 5.3%, which took the trading range below the 3-day low of $14.97 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLDX: 17.06 (+1.64)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.53 (-0.05), NWBO: 4.93 (+0.11), CVM: 0.65 (-0.02), CLDX: 17.06 (+1.64), INCY: 58.19 (+0.73), AZN: 71.43 (+0.67), MRK: 55.85 (-0.60), DNDN: 1.06 (+0.05), NLNK: 34.90 (-3.02), PPHM: 1.53 (+0.06), BMY: 54.20 (+0.67), FPRX: 13.15 (+0.49)
Celldex Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2014.
CLDX: 17.06 (+1.64)
Celldex Therapeutics Shares Down 9.6% Since SmarTrend's Sell Call (CLDX)
Comtex SmarTrend(R) - Mon Aug 04, 10:09AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on July 9th, 2014 at $14.39. In approximately 4 weeks, Celldex Therapeutics has returned 9.56% as of today's recent price of $13.01.
CLDX: 17.06 (+1.64)
3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 1.68 (unch), CLVS: 59.05 (+3.35), CLDX: 17.06 (+1.64), AZN: 71.43 (+0.67), GSK: 45.10 (-0.27)
Strong On High Volume: Celldex Therapeutics (CLDX)
at The Street - Wed Oct 15, 9:01AM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
CLDX: 17.06 (+1.64)
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics
PR Newswire - Wed Oct 15, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax Inc. (NASDAQ: NVAX), Galena Biopharma Inc. (NASDAQ: GALE), Geron Corporation (NASDAQ: GERN), and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 14, 2014, the NASDAQ Composite ended at 4,227.17, up 0.32%, the Dow Jones Industrial Average edged 0.04% lower, to finish the day at 16,315.19, and the S&P 500 closed at 1,877.70, up 0.16%. The gains were broad based as six out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, with the index also declining 1.35% in the previous three months. Register for your complimentary reports on these five stocks at:
GERN: 2.34 (+0.13), NVAX: 5.48 (-0.32), CLDX: 17.06 (+1.64), GALE: 2.06 (+0.06), ARIA: 5.97 (+0.23)
Celldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology
GlobeNewswire - Tue Sep 30, 3:08PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today the publication of two papers highlighting early studies of glembatumumab vedotin in breast cancer and metastatic melanoma in the Journal of Clinical Oncology (JCO). The papers, "A Phase 1/2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma" and "A Phase 1/2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Locally Advanced or Metastatic Breast Cancer" have been published as Early Release Articles on JCO's website and will appear in a future print edition.
CLDX: 17.06 (+1.64)
Celldex (CLDX) Up on Pilot Study Initiation on CDX-301 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 4:20PM CDT
Celldex Therapeutics, Inc. (CLDX) announced the commencement of a pilot study on CDX-301 alone and in combination with Mozobil for hematopoietic stem cell transplantation.
CBM: 19.88 (+1.34), GILD: 113.45 (+0.86), CLDX: 17.06 (+1.64), AMGN: 157.19 (+8.99)
Celldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
GlobeNewswire - Thu Sep 25, 7:05AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation (HSCT). The study will explore the utility of CDX-301, also known as FMS-like tyrosine kinase-3 ligand or Flt3L, alone and in combination with Mozobil(R) and is supported by preclinical data demonstrating that the combination of CDX-301 and Mozobil increased hematopoietic stem cell mobilization and improved transplantation of mobilized cells.
CLDX: 17.06 (+1.64)
Recombinant Therapeutic Proteins Market & Pipeline Analysis 2014
M2 - Thu Sep 18, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmpsjb/recombinant) has announced the addition of the "Recombinant Therapeutic Proteins Market & Pipeline Analysis" report to their offering. There are many driving forces for the recombinant proteins market. These include the introduction of new protein therapeutics and enhanced investments which are likely to significantly impact the growth of this industry in a positive manner. Additionally, the rapidly rising number of clinical trials would also help in surfacing the optimistic performance of the industry. In terms of segments, the major revenue-generating segments of the recombinant therapeutic protein market include monoclonal antibody, Insulin, Interferon Beta, G-CSF and coagulation factors. At present, owing to the fact that large number of companies is focusing their efforts in developing innovative treatment options using mAbs, this segment is currently the most dominant in terms of growth rate. In terms of the regional scenario of the recombinant proteins market, it has been observed that the US has been and would continue to account for the largest share of the global pie followed by the European countries. The emerging nations which are likely to be the future revenue generators for this market include the Asian and Middle-Eastern region, which is having a growing therapeutic market owing to improving economic scenario and financial capability of people. Report Highlights: - Global Market Overview - Mechanisms of Recombinant Protein Production - Types of Recombinant DNA Technology - Clinical Pipeline by Phase, Indication, Company, & Country - Marketed Recombinant Therapeutic Protein Drugs Clinical Insight - Recombinant Therapeutic Proteins Clinical Pipeline: 340 Drugs - Marketed Recombinant Therapeutic Protein Drugs : 83 Drugs - Majority Recombinant Therapeutic Proteins in Preclinical Phase: 128 Drugs Key Topics Covered: 1. What Are Recombinant Proteins? 2. Why There Exist Need for Recombinant Proteins? 3. Different Types of Recombinant DNA Technology 4. Mechanisms of Recombinant Protein Production 5. Global Recombinant Therapeutic Proteins Market Overview 6. Global Recombinant Therapeutic Proteins Market Dynamics 7. Recombinant Therapeutic Proteins Market Future Growth Outlook 8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country 9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country 10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country 11. Competitive Landscape - Boehringer Ingelheim - Bristol-Myers Squibb - Celldex Therapeutics - Eli Liily - GlaxoSmithKline - Merck - Novartis - Regeneron Pharmaceuticals - Roche - Shire Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lm...ecombinant
SHPG: 197.80 (+1.93), MRK: 55.85 (-0.60), CLDX: 17.06 (+1.64), GSK: 45.10 (-0.27), BMY: 54.20 (+0.67), REGN: 397.89 (-9.27), NVS: 92.35 (+2.14)
Global Burkitt Lymphoma Therapeutics Pipeline Review 2014 - 10 Drug Profiles from 4 Companies
M2 - Tue Sep 16, 11:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pgt84p/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Seattle Genetics, Inc. - Celldex Therapeutics, Inc. - Constellation Pharmaceuticals, Inc. Drug Profiles - varlilumab - SGN-CD19A - NSC-678515 - AZD-6738 - SH-7139 - Small Molecules to Inhibit BET for Cancer - Monoclonal Antibody Conjugated to Target CD20 for CLL and Burkitt Lymphoma - M-921 - SH-7133 - SH-7129 For more information visit http://www.researchandmarkets.com/research/pg...t_lymphoma
SGEN: 36.37 (+0.98), CLDX: 17.06 (+1.64), AZN: 71.43 (+0.67)
Why You Shouldn't Bet Against Celldex Therapeutics (CLDX) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:00AM CDT
Celldex Therapeutics (CLDX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 67 out of more than 250 industries.
CLDX: 17.06 (+1.64)
Global Cancer Vaccines Market & Pipeline Analysis Report 2014: 12 Marketed Vaccines & 289 Pipeline Vaccines
M2 - Mon Sep 08, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nnd4k6/global_cancer) has announced the addition of the "Global Cancer Vaccines Market & Pipeline Analysis" report to their offering. Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer. With the increasing focus of pharmaceutical companies in the cancer vaccine segment, the prophylactic vaccines segment grew substantially and currently is the largest source of revenue, with the therapeutic vaccines segment still remaining untapped. It is most likely that the regulatory authorities would in the near future quicken its approval process specifically for therapeutic vaccines. This coupled with a significant amount of investment for the research and development of these vaccines by the pharmaceutical companies would certainly push the overall cancer vaccines market onto a rapid growth trajectory. The current market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. Global Cancer Vaccines Market & Pipeline Analysis" Report Highlights: - Global Cancer Market Overview - Personalized Cancer Vaccines: Progress & Possibilities - Platforms for Cancer Vaccines Delivery - Cancer Vaccines: Mechanism & Innovations - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 289 Vaccines - Marketed Cancer Vaccines: 12 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Key Topics Covered: 1. Introduction to Cancer Vaccines 2. Cancer Vaccines: Mechanism & Innovations 3. Adjuvants Platforms for Cancer Vaccines Delivery 4. Global Cancer Vaccines Market Overview 5. Personalized Cancer Vaccines: Progress & Possibilities 6. Public HPV Cancer Vaccination Program 7. Global Cancer Vaccines Market Dynamics 8. Future Prospects of Cancer Vaccines 9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country 10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country 12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing 13. Competitive Landscape: Business Overview & Product Pipeline - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/nn...bal_cancer
NWBO: 4.93 (+0.11), MRK: 55.85 (-0.60), DNDN: 1.06 (+0.05), CLDX: 17.06 (+1.64), NLNK: 34.90 (-3.02), GALE: 2.06 (+0.06), IMUC: 0.70 (+0.01), NVS: 92.35 (+2.14)
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
SYN: 1.61 (+0.01), CPRX: 2.72 (+0.08), GERN: 2.34 (+0.13), CLDX: 17.06 (+1.64), NPSP: 28.12 (+0.80)
Celldex Announces Upcoming Presentation at the Morgan Stanley Healthcare Conference
GlobeNewswire - Wed Sep 03, 1:00PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Morgan Stanley Healthcare Conference on September 8, 2014 at 1:25 p.m. ET at the Grand Hyatt in New York City.
CLDX: 17.06 (+1.64), MS: 34.36 (+0.40)
Critical Alerts For General Electric, DSW, Celldex Therapeutics, Cognizant Technology Solutions and 3M Released By InvestorsObserver
PR Newswire - Wed Aug 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GE, DSW, CLDX, CTSH and MMM.
DSW: 31.26 (+0.66), MMM: 151.06 (+1.50), GE: 25.88 (+0.36), CLDX: 17.06 (+1.64), CTSH: 46.93 (+1.41)
Celldex Therapeutics (CLDX) Worth Watching: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:51AM CDT
Celldex Therapeutics, Inc. (CLDX) was a big mover last session, as its shares rose a little over 9% on the day.
CBPO: 57.78 (+1.66), CBM: 19.88 (+1.34), GILD: 113.45 (+0.86), CLDX: 17.06 (+1.64)
Look for Shares of Celldex Therapeutics to Potentially Pullback after Yesterday's 9.10% Rise
Comtex SmarTrend(R) - Tue Aug 26, 4:36PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $15.07 to a high of $17.00. Yesterday, the shares gained 9.1%, which took the trading range above the 3-day high of $15.33 on volume of 4.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CLDX: 17.06 (+1.64)
Today's Dead Cat Bounce Stock: Celldex Therapeutics (CLDX)
at The Street - Fri Aug 22, 12:19PM CDT
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate
CLDX: 17.06 (+1.64)
Celldex Therapeutics Falls 5.29% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Aug 21, 5:14PM CDT
Celldex Therapeutics (NASDAQ:CLDX) traded in a range yesterday that spanned from a low of $14.08 to a high of $15.23. Yesterday, the shares fell 5.3%, which took the trading range below the 3-day low of $14.97 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CLDX: 17.06 (+1.64)
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.53 (-0.05), NWBO: 4.93 (+0.11), CVM: 0.65 (-0.02), CLDX: 17.06 (+1.64), INCY: 58.19 (+0.73), AZN: 71.43 (+0.67), MRK: 55.85 (-0.60), DNDN: 1.06 (+0.05), NLNK: 34.90 (-3.02), PPHM: 1.53 (+0.06), BMY: 54.20 (+0.67), FPRX: 13.15 (+0.49)
Celldex Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 06, 3:02PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2014.
CLDX: 17.06 (+1.64)
Celldex Therapeutics Shares Down 9.6% Since SmarTrend's Sell Call (CLDX)
Comtex SmarTrend(R) - Mon Aug 04, 10:09AM CDT
SmarTrend identified a Downtrend for Celldex Therapeutics (NASDAQ:CLDX) on July 9th, 2014 at $14.39. In approximately 4 weeks, Celldex Therapeutics has returned 9.56% as of today's recent price of $13.01.
CLDX: 17.06 (+1.64)
